After 15 years, the Torlak Institute has produced a new vaccine against the seasonal flu, Torvaks Flu. Of the 14 countries that participated in the World Health Organization (WHO) project, only Serbia, Brazil and Vietnam were able to make the vaccine. The one produced by Torlak, which is under review at the Agency for Medicines and Medical Devices, is trivalent, containing two A types and one B type viruses. Once approved by the Agency, registration will follow, and next autumn immunization will begin, not with a French vaccine, but with a local one intended for the population of 18-65 years of age. Torlak’s Acting Director, Vera Stoiljkovic MD, points out that the trivalent vaccine will be produced every year. At the moment, 150,000 vaccines can be produced at a special laboratory in Torlak. However, each year this number will increase to a maximum of half a million doses. As production increases, work will be done on the composition of the vaccine to adapt it to the older population.